<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03975283</url>
  </required_header>
  <id_info>
    <org_study_id>SJHC80</org_study_id>
    <nct_id>NCT03975283</nct_id>
  </id_info>
  <brief_title>Use of Exparel for Postoperative Analgesia Following Bariatric Surgery</brief_title>
  <official_title>Use of Long-acting Local Analgesia in Bariatrics: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McMaster University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pacira Pharmaceuticals, Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>McMaster University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the efficacy of liposomal bupivicaine in post operative
      analgesia for patients undergoing bariatric surgery when compared to conventional local
      analgesia. Patients will be randomly selected to receive either liposomal bupivicaine or
      conventional bupivicaine via a transversus abdominal plane block during surgery. Patients
      will be followed post-operatively to assess use of narcotics, post-operative pain and nausea
      scores, and length of stay.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Optimizing pain management following bariatric surgery is an important aspect of patient care
      and post-surgical recovery. Despite advances in post-operative pain management, this remains
      a challenge and opioids continue to dominate as the most widely used analgesia for
      post-surgical pain management. Opioid use especially in the opioid-naive patient carries
      significant short term and long term risks including over dependence and chronic opioid use.

      Movements towards minimizing post-operative opioid use has shown regional anesthetic
      techniques to be highly effective in the management of pain in surgical patients. More
      specifically, liposomal bupivicaine (Exparel) is a novel non-opioid local analgesia that
      takes advantage of a multi-vesicular liposomal system to provide extended analgesia release
      over 72-96 hours.

      The purpose of this study to evaluate the use of liposomal bupivicaine in the management of
      post-operative pain following bariatric surgery via a transversus abdominis plane (TAP)
      block. Patients will be randomized to receiving either liposomal bupivicaine or traditional
      0.25% bupivicaine locally infiltrated at the time of bariatric surgery. Both liposomal
      bupivicaine and traditional bupivicaine will be administered via TAP block after
      identification of planes via laparoscopy by the bariatric surgeon.

      Patients will be followed post-operatively to assess use of opioid analgesia between the two
      arms. In addition, they will be assessed with respect to pain and nausea using analog scores,
      as well as hospital length of stay.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2019</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of liposomal bupivicaine via TAP block in eliminating narcotic use post-operatively</measure>
    <time_frame>10 days</time_frame>
    <description>Proportion of patients requiring narcotics post-procedure until discharge as recorded via their electronic medical record.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Analog pain scores</measure>
    <time_frame>10 days (or until discharge)</time_frame>
    <description>Pain will be assessed in the post-anaesthesia care unit (PACU) at 2 occasions - upon arrival and before transfer to ward. Subsequently, pain scores will then be reassessed at 8 am, 2 pm, and 8pm until discharge. Pain will be measured on an 11-point scale from 0 (no pain) to 10 (most pain imaginable) and the average of the PACU and ward scores will be used as the final outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-operative nausea</measure>
    <time_frame>10 days (or until discharge)</time_frame>
    <description>Postoperative nausea scores will be assessed daily at 8 am, 2 pm, and 8pm until discharge using an 11-point scale from 0 (no nausea) to 10 (most nausea imaginable)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-operative Narcotic Use</measure>
    <time_frame>10 days (or until discharge)</time_frame>
    <description>Postoperative narcotic use will be recorded in morphine equivalent units and recorded via their electronic medical record.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Length of Stay</measure>
    <time_frame>Total length of stay will be calculated from registration until discharge to home; usually spans 2-5 days.</time_frame>
    <description>Length of stay calculated in hours</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Post Operative Pain</condition>
  <arm_group>
    <arm_group_label>Exparel (Liposomal Bupivicaine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 ml vial of liposomal bupivacaine containing 266 mg (maximum dose), will be diluted with 20 ml of 0.25% bupivacaine (containing 50 mg of bupivacaine) and 20 ml saline (60 ml total). That total volume will be divided into two 30 ml syringes, and each will be used (per side) for the TAP blocks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.25% Bupivicaine HCL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Two 30 ml of 0.25% bupivacaine is drawn up and given on each side after identification of planes and levels via laparoscopy. Medication will be given just below the last rib and extend to below the lowest incision.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exparel 266 MG Per 20 ML Injection</intervention_name>
    <description>266mg of liposomal bupivacaine 266 mg, 20 mL volume, will be diluted with 20 ml of 0.25% bupivacaine (50 mg of bupivacaine) and 20 ml saline, thereby totalling 60mL volume. Total volume will be divided into two 30 ml syringes, and each will be used (per side) for the TAP blocks.</description>
    <arm_group_label>Exparel (Liposomal Bupivicaine)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine Hcl 0.25% Inj</intervention_name>
    <description>0.25% bupivacaine, 60mL total, divided into two 30mL syringes and delivered via TAP block on either side.</description>
    <arm_group_label>0.25% Bupivicaine HCL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient previously met NIH criteria for bariatric surgery and has not received a
             previous bariatric surgical procedure

          -  The patient is aged 18-65 years and has completed the screening and preparation
             process prescribed by the Ontario Bariatric Network

        Exclusion Criteria:

          -  Inability to give informed consent

          -  ASA &gt; 4

          -  Planned procedure other than Roux-en-Y gastric bypass (RYGB) or contraindications to
             RYGB

          -  BMI &gt; 55 kg/m2

          -  Revisional procedure

          -  Allergies or suspected allergies to local anesthetic medications (bupivicaine)

          -  Renal insufficiency (GFR &lt; 30ml/min)

          -  History of chronic pain needing daily medications for the last &gt;3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Margherita Cadeddu, MD, FRCSC</last_name>
    <role>Principal Investigator</role>
    <affiliation>McMaster University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karen Barlow</last_name>
    <phone>905-522-1155</phone>
    <phone_ext>33739</phone_ext>
    <email>kbarlow@stjoes.ca</email>
  </overall_contact>
  <reference>
    <citation>Raebel MA, Newcomer SR, Bayliss EA, Boudreau D, DeBar L, Elliott TE, Ahmed AT, Pawloski PA, Fisher D, Toh S, Donahoo WT. Chronic opioid use emerging after bariatric surgery. Pharmacoepidemiol Drug Saf. 2014 Dec;23(12):1247-57. doi: 10.1002/pds.3625. Epub 2014 Apr 14.</citation>
    <PMID>24733580</PMID>
  </reference>
  <reference>
    <citation>Chahar P, Cummings KC 3rd. Liposomal bupivacaine: a review of a new bupivacaine formulation. J Pain Res. 2012;5:257-64. doi: 10.2147/JPR.S27894. Epub 2012 Aug 14.</citation>
    <PMID>23049275</PMID>
  </reference>
  <reference>
    <citation>Dasta J, Ramamoorthy S, Patou G, Sinatra R. Bupivacaine liposome injectable suspension compared with bupivacaine HCl for the reduction of opioid burden in the postsurgical setting. Curr Med Res Opin. 2012 Oct;28(10):1609-15. doi: 10.1185/03007995.2012.721760. Epub 2012 Sep 3.</citation>
    <PMID>22900785</PMID>
  </reference>
  <reference>
    <citation>Cohen SM. Extended pain relief trial utilizing infiltration of Exparel(®), a long-acting multivesicular liposome formulation of bupivacaine: a Phase IV health economic trial in adult patients undergoing open colectomy. J Pain Res. 2012;5:567-72. doi: 10.2147/JPR.S38621. Epub 2012 Nov 20.</citation>
    <PMID>23204866</PMID>
  </reference>
  <reference>
    <citation>Bhakta A, Glotzer O, Ata A, Tafen M, Stain SC, Singh PT. Analgesic efficacy of laparoscopic-guided transverse abdominis plane block using liposomal bupivacaine in bariatric surgery. Am J Surg. 2018 Apr;215(4):643-646. doi: 10.1016/j.amjsurg.2017.09.006. Epub 2017 Sep 20.</citation>
    <PMID>29061282</PMID>
  </reference>
  <reference>
    <citation>Boerboom SL, de Haes A, Vd Wetering L, Aarts EO, Janssen IMC, Geurts JW, Kamphuis ET. Preperitoneal Bupivacaine Infiltration Reduces Postoperative Opioid Consumption, Acute Pain, and Chronic Postsurgical Pain After Bariatric Surgery: a Randomized Controlled Trial. Obes Surg. 2018 Oct;28(10):3102-3110. doi: 10.1007/s11695-018-3341-6.</citation>
    <PMID>29926357</PMID>
  </reference>
  <reference>
    <citation>Ilfeld BM, Viscusi ER, Hadzic A, Minkowitz HS, Morren MD, Lookabaugh J, Joshi GP. Safety and Side Effect Profile of Liposome Bupivacaine (Exparel) in Peripheral Nerve Blocks. Reg Anesth Pain Med. 2015 Sep-Oct;40(5):572-82. doi: 10.1097/AAP.0000000000000283.</citation>
    <PMID>26204387</PMID>
  </reference>
  <reference>
    <citation>Surdam JW, Licini DJ, Baynes NT, Arce BR. The use of exparel (liposomal bupivacaine) to manage postoperative pain in unilateral total knee arthroplasty patients. J Arthroplasty. 2015 Feb;30(2):325-9. doi: 10.1016/j.arth.2014.09.004. Epub 2014 Sep 16.</citation>
    <PMID>25282071</PMID>
  </reference>
  <reference>
    <citation>Bramlett K, Onel E, Viscusi ER, Jones K. A randomized, double-blind, dose-ranging study comparing wound infiltration of DepoFoam bupivacaine, an extended-release liposomal bupivacaine, to bupivacaine HCl for postsurgical analgesia in total knee arthroplasty. Knee. 2012 Oct;19(5):530-6. doi: 10.1016/j.knee.2011.12.004. Epub 2012 Jan 28.</citation>
    <PMID>22285545</PMID>
  </reference>
  <reference>
    <citation>Ilfeld BM, Malhotra N, Furnish TJ, Donohue MC, Madison SJ. Liposomal bupivacaine as a single-injection peripheral nerve block: a dose-response study. Anesth Analg. 2013 Nov;117(5):1248-56. doi: 10.1213/ANE.0b013e31829cc6ae.</citation>
    <PMID>24108252</PMID>
  </reference>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>May 31, 2019</study_first_submitted>
  <study_first_submitted_qc>June 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 5, 2019</study_first_posted>
  <last_update_submitted>June 4, 2019</last_update_submitted>
  <last_update_submitted_qc>June 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No plan to share individual participant data</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

